BioWorld

Sep. 9, 2010

ZymoGenetics Skyrockets 84% on $885M BMS Offer

ZymoGenetics Inc. is the latest treasure Bristol-Myers Squibb Co. is seeking to add its string of pearls under the pharma giant's 2007 strategy to grow its R&D pipeline, offering $9.75 per share for the Seattle biotech, or about $885 million. (BioWorld Today) Read More

For $339M Onyx Carves Out Carfilzomib Japanese Rights

Two Studies Identify Same Culprit In Ovarian Cancer

Jennerex, Transgene in $116M Deal; Liver Cancer Trial First

Zyngenia Adds $15M to Push Multitarget Antibodies to IND

Vertex Reports Positive HCV Data, 65% Overall Viral Cure

Stock Movers

Clinic Roundup

Other News To Note

Today's news in brief

BioWorld

Illustration of SCAN in Parkinson’s vs healthy subcortex

SCAN is core circuit affected in Parkinson’s disease

BioWorld

Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...

3D rendering of skin cells and elastin with collagen layer

First-in-class pan-inflammasome blocker for hidradenitis suppurativa

BioWorld Science

Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.

Illustration of cancer cell in crosshairs being destroyed

RX-10616 improves radiotherapy efficacy in HNSCC

BioWorld Science

Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...

CROI 2026: Neurodegeneration, the challenge of aging with HIV

BioWorld

Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...